Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Primrose Schools, a national preschool franchise company, is on a positive growth track that now spans six years. In 2016, the company saw year-over-year revenue growth of 13 percent from 2015, strengthening its brand leadership position in the highly competitive early childhood education franchise industry.
Primrose has 342 locations around the country that provide high-quality early education and care to children and families in 27 states. Schools had an average occupancy rate of 87.7 percent, as measured in May 2016. Primrose opened 30 new schools and awarded 46 franchise agreements in 2016, and the company anticipates opening 34 new schools in 2017.
To view the multimedia release go to:
http://www.multivu.com/players/English/7727754-primrose-schools-available-franchise-locations/
Der Audi A1 Sportback, der Anfang 2012 zu den Händlern rollt, ist der fünftürige Kompakt-Audi für ein junges, urbanes Publikum. Im Design, beim Aufbau der leichten Karosserie und in den Abmessungen ist der 3,95 Meter lange Neue eng mit seinem dreitürigen Schwestermodell verwandt. Er baut um einige Millimeter höher, damit bietet er mehr Platz auf der Rücksitzbank. Audi liefert den A1 Sportback serienmäßig mit vier, auf Wunsch ohne Aufpreis mit fünf Sitzen aus.
Als Antrieb stehen vier TFSI-Benziner und drei TDI bereit, ihre Leistungsspanne reicht von 63 kW (86 PS) bis 136 kW (185 PS). Für einige Motoren liefert Audi die blitzschnell schaltende Siebengang S tronic als Kraftübertragung.
http://multivu.prnewswire.com/mnr/prne/audi/52784/
Do you know the three most important tips when it comes to caring for your tyres? For more detail you can check it to our website www.tyrepower.com.au/. Learning and implementing general tyre maintenance will help extend the life of tyres. Driving style is a key component. A conservative driving style will ensure even tread wear and prolong tyre life. Tread wear is an issue that not all drivers are aware of. Follow these simple tips so you can check the tread wear on your tyres and replace them before they become dangerous to drive on. Once a tyre has less than 1.6 mm of tread wear it is no longer roadworthy and must be replaced. This video shows you how to measure tread wear and what signs to look out for. Parking is also a key element of tyre care. High impact contact with kerbs and other barriers or structures may damage your tyres. If in doubt about any aspects of tyre care, tread wear or when to replace tyres, contact your nearest Tyrepower store for expert and friendly advice.
Educators and parents agree that there is a direct correlation between the way kids play and how they learn. With edu-gaming on the rise, parents are looking for new ways to provide a playful, educational experience for their children.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/vtech/44431/
In the lead-up to Lung Cancer Awareness Month this November, the ‘future face’ of women’s cancer is being revealed. While new data published last month by Cancer Research UK suggests the number of women dying from breast cancer in the UK is in decline – expected to drop almost 30 percent by 2030 – the number of women dying from lung cancer is on the increase.
Liz Darlison, Macmillan Consultant Nurse Specialist, University Hospitals of Leicester, says, “While the statistics paint a frightening picture, there’s a great deal that can be done to help ensure women are diagnosed earlier, treated earlier and live longer. By raising awareness of the tell-tale signs – for example, a persistent cough that lasts longer than three weeks – there’s the potential to save thousands of lives every year.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/56634-lilly-uk-lung-cancer-awareness
Today, Easter Seals released the Spanish version of the online developmental screening, the Ages & Stages Questionnaires® (ASQ), making it one step closer to its goal of having all kids under five screened for developmental delays, autism and other disabilities, and allowing for every family to access the screening free of charge.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55359-easter-seals-week-of-the-young-child-free-online-developmental-screening
Easter Seals, one of the country’s leading providers of child development services, introduces a new video with a cast of animated characters to help parents understand the importance of monitoring their child’s development. Make the First Five Count (makethefirstfivecount.org) is a movement to ensure all children are entering kindergarten with the right skills to succeed alongside their peers.
“Easter Seals is dedicated to ensuring all children have every opportunity to reach their full potential,” said Katy Beh Neas, Easter Seals’ Executive Vice President of Government Relations. “We’ve created this new video to help parents learn the basics of child development. At the new website, parents can find a screening tool and other information designed to support the well-being of children. Monitoring development should be treated as a common part of our annual routines, like spring cleaning or a trip to the dentist.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7172751-easter-seals-make-the-first-five-count/
In honor of World Pancreatic Cancer Day on Nov. 16, people around the world will come together to Demand Better in the fight against the world’s toughest cancer, starting with earlier diagnosis. The annual one-day campaign is an initiative of the World Pancreatic Cancer Coalition, which is comprised of more than 60 organizations from 27 countries on six continents.
Every day, more than 1,000 people worldwide will be diagnosed with pancreatic cancer. Of that, an estimated 985 will die from the disease. Additionally, pancreatic cancer has the lowest survival rate among all major cancers, and in nearly every country, it is the only major cancer with a single-digit five-year survival rate (2-9 percent). These stunning figures are not merely statistics, they represent family members, friends and colleagues on every corner of the globe.
“This year, we are turning World Pancreatic Cancer Day from a day of awareness to a day of action,” said Julie Fleshman, JD, MBA, World Pancreatic Cancer Coalition chair. “As we expand our global movement to end pancreatic cancer, we are demanding better for pancreatic cancer patients now and in the future.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8201651-world-pancreatic-cancer-day-demand-better/
